News
Eli Lilly's Jaypirca met its non-inferiority primary endpoint, trumping Imbruvica in patient overall response rate (ORR).
Roche’s Alzheimer’s disease therapy has continued to show benefit for patients after 28 weeks in a long-term extension study. In the high-dose cohort from the ongoing Phase Ib/IIa Brainshuttle AD ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback